CRMD Research Coverage

 

745 Route 202-206, Suite 303
Bridgewater, NJ 08807
Phone: 908-517-9500
Fax: 908-429-4307

CorMedix News Room

Current Articles | RSS Feed RSS Feed

CorMedix (AMEX:CRMD) - Rodman & Renshaw wrap-up

Posted by Mike Sweeney on Thu, Sep 23, 2010 @ 09:01
  
  
  
  
Add to delicious  delicious  
  
  

crmd logoLast week, CorMedix (AMEX: CRMD) presented at Rodman & Renshaw's 2010 Annual Global Investment Conference in New York. UNIS was one of the featured corporate presentations in the Healthcare tract.The focus of the presentation was:

  • Two products entering late stage clinical development;
  • Reduced development and regulatory risk;
  • Pipeline of additional products and indications;
  • World commercialization rights.

CRMD Rodman & Renshaw Conference Presentation

About Rodman & Renshaw

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM) is a holding company with a number of direct and indirect subsidiaries, including Rodman & Renshaw, LLC.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005.

For more information visit Rodman & Renshaw on the Internet at www.rodm.com

About CorMedix

CorMedix Inc. is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications, in effect, treating the kidney to treat the heart. CorMedix currently has several product candidates in development, including its two most advanced product candidates: CRMD003 (Neutrolin®) for the prevention of central venous catheter infection and clotting in hemodialysis; and CRMD001 (a proprietary formulation of deferiprone) for the prevention of contrast-induced nephropathy in high-risk patients with chronic kidney disease. Please see www.cormedix.com for additional information.

Tags: , , , , , , , , , , , ,

Comments

Currently, there are no comments. Be the first to post one!
Post Comment
Name
 *
Email
 *
Website (optional)
Comment
 *

Allowed tags: <a> link, <b> bold, <i> italics

CorMedix (AMEX:CRMD-U)

CorMedix Inc. (AMEX:CRMD-U) is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and kidney (cardiorenal) disease.

Cardiorenal disease includes a broad range of inter-related cardiovascular, kidney and metabolic problems which share the common trait of underlying oxidative stress and blood vessel malfunction (endothelial dysfunction).